Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.48 |
| ▸ | ABCB1 | P08183 | 10/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8706914 | 0.99 | HRH3 (0.47) | HRH3ABCB1MEN1KMT2ATP53 | |
| SCHEMBL8703946 | 0.92 | ABCB1 (0.57) | ABCB1MEN1KMT2ATP53CYP3A4 | |
| SCHEMBL8703339 | 0.91 | ABCB1 (0.56) | ABCB1MEN1KMT2ATP53CYP3A4 | |
| SCHEMBL8703273 | 0.91 | ABCB1 (0.56) | ABCB1MEN1KMT2ATP53CYP3A4 | |
| Hydrochloric Acid SCHEMBL8702858 | 0.91 | ABCB1 (0.56) | ABCB1MEN1KMT2ATP53CYP3A4 | |
| SCHEMBL8709024 | 0.88 | CHRNB2 (0.48) | HRH3 | |
| SCHEMBL8702137 | 0.88 | HRH3 (0.53) | HRH3MEN1KMT2A | |
| SCHEMBL8703661 | 0.87 | CHRNB2 (0.48) | HRH3 | |
| SCHEMBL8707213 | 0.87 | CHRNB2 (0.48) | HRH3 | |
| Hydrochloric Acid SCHEMBL27425800 | 0.87 | HRH3 (0.52) | HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0844000-A1 | Use of alpha, omega-diarylalkane derivatives in the treatment and prevention of psychosis | SANKYO COMPANY LIMITED (JP) | 1998-05-27 | — | — | EP | claimed |
| US-5556864-A | TREATMENT OF CIRCULATORY DISEASES AND PSYCHOSIS | SANKYO COMPANY, LIMITED (JP) | 1996-09-17 | — | — | US | claimed |
| EP-0600717-A1 | Phenoxyalkylamines, -pyrrolidines and -piperidines for the treatment and prevention of circulatory diseases and psychosis | SANKYO COMPANY LIMITED (JP) | 1994-06-08 | — | — | EP | claimed |
| EP-0844000-A1 | Use of alpha, omega-diarylalkane derivatives in the treatment and prevention of psychosis | SANKYO COMPANY LIMITED (JP) | 1998-05-27 | — | — | EP | disclosed |
| US-5556864-A | TREATMENT OF CIRCULATORY DISEASES AND PSYCHOSIS | SANKYO COMPANY, LIMITED (JP) | 1996-09-17 | — | — | US | disclosed |
| EP-0600717-A1 | Phenoxyalkylamines, -pyrrolidines and -piperidines for the treatment and prevention of circulatory diseases and psychosis | SANKYO COMPANY LIMITED (JP) | 1994-06-08 | — | — | EP | disclosed |